124 related articles for article (PubMed ID: 24252244)
21. Neuron-to-neuron α-synuclein propagation in vivo is independent of neuronal injury.
Ulusoy A; Musgrove RE; Rusconi R; Klinkenberg M; Helwig M; Schneider A; Di Monte DA
Acta Neuropathol Commun; 2015 Mar; 3():13. PubMed ID: 25853980
[TBL] [Abstract][Full Text] [Related]
22. Accumulation of Alpha-Synuclein and Increase in the Inflammatory Response in the
Valdés-Fuentes M; Rodríguez-Martínez E; Rivas-Arancibia S
Int J Mol Sci; 2024 May; 25(10):. PubMed ID: 38791561
[TBL] [Abstract][Full Text] [Related]
23. Retraction Note: Gintonin Mitigates MPTP-Induced Loss of Nigrostriatal Dopaminergic Neurons and Accumulation of α-Synuclein via the Nrf2/HO-1 Pathway.
Jo MG; Ikram M; Jo MH; Yoo L; Chung KC; Nah SY; Hwang H; Rhim H; Kim MO
Mol Neurobiol; 2024 Apr; ():. PubMed ID: 38625622
[No Abstract] [Full Text] [Related]
24. Erratum to "Levels of α- and β-synuclein regulate cellular susceptibility to toxicity from a- synuclein oligomers".
FASEB J; 2024 Jul; 38(13):e23755. PubMed ID: 38888817
[No Abstract] [Full Text] [Related]
25. Parkinson disease in 2015: Evolving basic, pathological and clinical concepts in PD.
Kalia LV; Lang AE
Nat Rev Neurol; 2016 Feb; 12(2):65-6. PubMed ID: 26782330
[No Abstract] [Full Text] [Related]
26. Targeting α-synuclein oligomers by protein-fragment complementation for drug discovery in synucleinopathies.
Moussaud S; Malany S; Mehta A; Vasile S; Smith LH; McLean PJ
Expert Opin Ther Targets; 2015 May; 19(5):589-603. PubMed ID: 25785645
[TBL] [Abstract][Full Text] [Related]
27. Where are we with surgical therapies for Parkinson's disease?
Strauss I; Kalia SK; Lozano AM
Parkinsonism Relat Disord; 2014 Jan; 20 Suppl 1():S187-91. PubMed ID: 24262178
[TBL] [Abstract][Full Text] [Related]
28. Transmission of Soluble and Insoluble α-Synuclein to Mice.
Jones DR; Delenclos M; Baine AT; DeTure M; Murray ME; Dickson DW; McLean PJ
J Neuropathol Exp Neurol; 2015 Dec; 74(12):1158-69. PubMed ID: 26574670
[TBL] [Abstract][Full Text] [Related]
29. Chronic treatment with novel small molecule Hsp90 inhibitors rescues striatal dopamine levels but not α-synuclein-induced neuronal cell loss.
McFarland NR; Dimant H; Kibuuka L; Ebrahimi-Fakhari D; Desjardins CA; Danzer KM; Danzer M; Fan Z; Schwarzschild MA; Hirst W; McLean PJ
PLoS One; 2014; 9(1):e86048. PubMed ID: 24465863
[TBL] [Abstract][Full Text] [Related]
30. Features of alpha-synuclein that could explain the progression and irreversibility of Parkinson's disease.
Gallegos S; Pacheco C; Peters C; Opazo CM; Aguayo LG
Front Neurosci; 2015; 9():59. PubMed ID: 25805964
[TBL] [Abstract][Full Text] [Related]
31. Anti-human α-synuclein N-terminal peptide antibody protects against dopaminergic cell death and ameliorates behavioral deficits in an AAV-α-synuclein rat model of Parkinson's disease.
Shahaduzzaman M; Nash K; Hudson C; Sharif M; Grimmig B; Lin X; Bai G; Liu H; Ugen KE; Cao C; Bickford PC
PLoS One; 2015; 10(2):e0116841. PubMed ID: 25658425
[TBL] [Abstract][Full Text] [Related]
32. A53T human α-synuclein overexpression in transgenic mice induces pervasive mitochondria macroautophagy defects preceding dopamine neuron degeneration.
Chen L; Xie Z; Turkson S; Zhuang X
J Neurosci; 2015 Jan; 35(3):890-905. PubMed ID: 25609609
[TBL] [Abstract][Full Text] [Related]
33. Altered network connectivity in frontotemporal dementia with C9orf72 hexanucleotide repeat expansion.
Lee SE; Khazenzon AM; Trujillo AJ; Guo CC; Yokoyama JS; Sha SJ; Takada LT; Karydas AM; Block NR; Coppola G; Pribadi M; Geschwind DH; Rademakers R; Fong JC; Weiner MW; Boxer AL; Kramer JH; Rosen HJ; Miller BL; Seeley WW
Brain; 2014 Nov; 137(Pt 11):3047-60. PubMed ID: 25273996
[TBL] [Abstract][Full Text] [Related]
34. Bilateral pallidal stimulation for sargoglycan epsilon negative myoclonus.
Sidiropoulos C; Mestre T; Hutchison W; Moro E; Valencia A; Poon YY; Fallis M; Rughani AI; Kalia SK; Lozano AM; Lang AE
Parkinsonism Relat Disord; 2014 Aug; 20(8):915-8. PubMed ID: 24812007
[TBL] [Abstract][Full Text] [Related]
35. Unbiased screen for interactors of leucine-rich repeat kinase 2 supports a common pathway for sporadic and familial Parkinson disease.
Beilina A; Rudenko IN; Kaganovich A; Civiero L; Chau H; Kalia SK; Kalia LV; Lobbestael E; Chia R; Ndukwe K; Ding J; Nalls MA; ; ; Olszewski M; Hauser DN; Kumaran R; Lozano AM; Baekelandt V; Greene LE; Taymans JM; Greggio E; Cookson MR
Proc Natl Acad Sci U S A; 2014 Feb; 111(7):2626-31. PubMed ID: 24510904
[TBL] [Abstract][Full Text] [Related]
36. Assessment of the Anti-Amyloidogenic Properties of Essential Oils and Their Constituents in Cells Using a Whole-Cell Recombinant Biosensor.
Stylianopoulou E; Daviti A; Giourou V; Gerasimidi E; Nikolaou A; Kourkoutas Y; Grigoriou ME; Paleologou KE; Skavdis G
Brain Sci; 2023 Dec; 14(1):. PubMed ID: 38248250
[TBL] [Abstract][Full Text] [Related]
37. Advancements in a FRET Biosensor for Live-Cell Fluorescence-Lifetime High-Throughput Screening of Alpha-Synuclein.
Braun AR; Kochen NN; Yuen SL; Liao EE; Cornea RL; Thomas DD; Sachs JN
ASN Neuro; 2023; 15():17590914231184086. PubMed ID: 37428128
[TBL] [Abstract][Full Text] [Related]
38. Disrupting the α-synuclein-ESCRT interaction with a peptide inhibitor mitigates neurodegeneration in preclinical models of Parkinson's disease.
Nim S; O'Hara DM; Corbi-Verge C; Perez-Riba A; Fujisawa K; Kapadia M; Chau H; Albanese F; Pawar G; De Snoo ML; Ngana SG; Kim J; El-Agnaf OMA; Rennella E; Kay LE; Kalia SK; Kalia LV; Kim PM
Nat Commun; 2023 Apr; 14(1):2150. PubMed ID: 37076542
[TBL] [Abstract][Full Text] [Related]
39. Monitoring α-synuclein aggregation.
Estaun-Panzano J; Arotcarena ML; Bezard E
Neurobiol Dis; 2023 Jan; 176():105966. PubMed ID: 36527982
[TBL] [Abstract][Full Text] [Related]
40.
Forloni G; La Vitola P; Balducci C
Front Neurosci; 2022; 16():822420. PubMed ID: 36081661
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
